Research from Pittsburgh explores the potential of next-generation mRNA vaccines to be more cost-effective and efficient. Despite initial funding for mRNA vaccine development during the COVID-19 pandemic, recent skepticism from government officials has raised concerns about the technology’s safety and efficacy. President Donald Trump’s administration canceled a significant contract for an mRNA flu vaccine, citing doubts about its testing and effectiveness. Health and Human Services Secretary Robert F. Kennedy Jr. has also expressed reservations about the technology, labeling it as ‘under-tested.’ These developments highlight the ongoing debate surrounding mRNA vaccines and their future role in public health protection.
Read more from wesa.fm